Application of Electronic Endoscope in Fetal Distress
NCT06608654
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases and Pregnancy Complications
Nanjing, Jiangsu, China
View Trial DetailsNCT Number: NCT07827222
Cardiotocography (CTG) is the standard method for monitoring fetal heart rate and uterine contractions during labor to detect signs of fetal hypoxia. However, human CTG interpretation is often subjective and subject to high interobserver variability, even among experienced clinicians. Multimodal artificial intelligence (AI) models have emerged as potential diagnostic aids capable of evaluating CTG tracings. This prospective diagnostic accuracy study aims to evaluate the diagnostic performance of Gemini Flash 3.6 in interpreting intrapartum CTG recordings according to the 2015 International Federation of Gynecology and Obstetrics (FIGO) guidelines, and to compare its accuracy directly against independent human expert obstetricians.
Participants include pregnant women admitted in active labor at term with a singleton cephalic pregnancy undergoing continuous CTG monitoring. De-identified digital images of the final 60 minutes of CTG tracing prior to delivery will be independently evaluated by Gemini Flash 3.6 and three expert obstetricians. Each evaluator will classify the tracings into one of three FIGO categories: Normal, Suspicious, or Pathological. All evaluators will be blinded to clinical details, delivery outcomes, and other observers' interpretations.
The primary objective is to assess the diagnostic sensitivity of Gemini Flash 3.6 in identifying neonates with a 5-minute Apgar score less than 7. Secondary objectives include comparing the diagnostic performance of the AI model with that of individual expert obstetricians, measuring interobserver agreement among all raters, and assessing associations with 1-minute Apgar scores and umbilical artery blood gas parameters. The AI model will be used solely as an investigational research tool, and its evaluations will not be available to the clinical team or used to guide patient care.
Trial opening soon.
Get Notified18 year and older
Female
Observational
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 5 minutes after birth
Sensitivity is defined as the percentage of neonates with a confirmed 5-minute Apgar score less than 7 who are correctly identified as having a "Pathological" CTG tracing by Gemini Flash 3.6. Intrapartum CTG tracings from the final 60 minutes of labor immediately preceding delivery are interpreted according to the 2015 FIGO guidelines. For binary diagnostic performance analysis, a "Pathological" CTG represents a positive test result, while "Normal" and "Suspicious" CTGs represent negative test results. Sensitivity is calculated as [True Positives / (True Positives + False Negatives)] * 100 and reported with a 95% confidence interval.
Assiut University
Other
Gemini Flash 3.6 Versus Human Observers for FIGO-Based Interpretation of Intrapartum Cardiotocography: A Diagnostic Accuracy Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06608654
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases and Pregnancy Complications
Nanjing, Jiangsu, China
View Trial DetailsNCT05681624
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases and Pregnancy Complications
St Louis, Missouri, United States
View Trial DetailsNCT06405984
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases and Pregnancy Complications
Norfolk, Virginia, United States
View Trial DetailsNCT07296419
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases and Pregnancy Complications
Shreveport, Louisiana, United States
View Trial Details